

ASX ANNOUNCEMENT

12 July 2021

ADAPT[®] Manufacturing Breakthrough

Brisbane, Australia and Minneapolis USA, Anteris Technologies Ltd (ASX: AVR) (Anteris or the Company), announces a breakthrough in manufacturing the tissue used in ADAPT[®] treated products from bovine pericardium.

Anteris has developed specialized machinery to create consistently thin tissue through an innovative processing technique. This process reduces the native pericardium thickness to yield tissue with the desired thickness to make its 3D single-piece aortic valves.

Thinning tissue on-demand is a challenging engineering feat, achieved by several custom equipment iterations and parameter adjustments. Tissue tests demonstrated tensile strength properties equivalent to current ADAPT[®] treated pericardium.

Valve durability studies proving absolute equivalence between the processed tissue and native (thin) tissue are the confirmatory next step.

Key points

- Prior to AVR's success, the ability to thin tissue was not achievable.
- This accomplishment took several years with a specialized machine the Company built from the ground up.
- This technique once proven up at commercial scale has the ability to increase yields and decrease manufacturing costs.

Importantly, Anteris has lodged patent applications to protect its intellectual property in this breakthrough development.

ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company delivering clinically superior and durable solutions through better science and better design. Its focus is on developing next generation technologies that help healthcare professionals create life-changing outcomes for patients.

The Anteris DurAVR[™] aortic replacement valve addresses the acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.

Anteris Technologies Ltd

Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

Customer Service:

T +61 1300 550 310 | F +61 1300 972 437 | E info@anteristech.com | W anteristech.com

Brisbane • Minneapolis • Geneva • Malaga





The proven benefits of its ADAPT[®] tissue technology, paired with DurAVR[™]'s unique 3D single-piece aortic valve design, has the potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to the challenges facing heart surgeons today.

Authorisation and Additional information

This announcement was authorised by Mr Wayne Paterson, Chief Executive Officer.

For more information:

Trina Raymond

WE Communications

E: WE-AUAnterisTech@we-worldwide.com

P: +61 420 316 449

www.anteristech.com

Twitter: @AnterisTech

Facebook: www.facebook.com/AnterisTech